Anti-Parkinsonian Medicines: Complete Pharmacology and Nursing Care
Anti-Parkinsonian medicines are medicines used to improve motor and selected non-motor symptoms of Parkinson disease, or—using different choices—to manage drug-induced parkinsonism and other extrapyramidal symptoms. They improve symptoms but do not cure Parkinson disease or reliably stop its progression.
Critical distinction: idiopathic Parkinson disease results mainly from degeneration of dopaminergic neurons and is commonly treated by increasing or imitating dopamine. Antipsychotic-induced parkinsonism results from dopamine D2 receptor blockade; management begins with review of the causative medicine, and short-term anticholinergic treatment may be used when appropriate. Levodopa and dopamine agonists can worsen psychosis and are generally not routine treatments for antipsychotic-induced parkinsonism.
Relevant Pharmacology and Therapeutic Goals
Loss of dopamine in the nigrostriatal pathway creates a relative excess of cholinergic activity within the basal ganglia. This produces bradykinesia, rigidity, resting tremor and postural impairment. Treatment therefore aims to:
- Replace dopamine precursor with levodopa.
- Directly stimulate dopamine receptors with dopamine agonists.
- Reduce dopamine breakdown using MAO-B or COMT inhibitors.
- Increase dopamine release/reduce glutamatergic activity with amantadine.
- Reduce relative cholinergic excess with central antimuscarinics, especially for tremor or selected drug-induced extrapyramidal symptoms.
Choice is individualised according to symptom impact, age, cognition, falls, psychosis, comorbidities, pregnancy, occupation, medicine availability, patient preference and cost. If motor symptoms affect quality of life, NICE recommends offering levodopa.
Classification
| Class | Examples | Main place in therapy |
|---|---|---|
| Dopamine precursor + peripheral decarboxylase inhibitor | Levodopa/carbidopa; levodopa/benserazide | Most effective symptomatic treatment for bradykinesia and rigidity; also improves tremor. |
| Non-ergot dopamine agonists | Pramipexole, ropinirole, rotigotine; apomorphine for advanced “off” episodes | Monotherapy in selected early disease or adjunct to levodopa. |
| Ergot dopamine agonists | Bromocriptine, cabergoline | Rarely preferred because of fibrotic and valvular risks; specialist monitoring required. |
| MAO-B inhibitors | Selegiline, rasagiline, safinamide | Early mild symptoms or adjunct for wearing-off. |
| COMT inhibitors | Entacapone, opicapone, tolcapone | Adjunct to levodopa for end-of-dose wearing-off; no useful effect without levodopa. |
| Dopaminergic/NMDA antagonist | Amantadine | Modest motor benefit; often considered for levodopa-induced dyskinesia. |
| Central antimuscarinics | Trihexyphenidyl (benzhexol), benztropine, biperiden, procyclidine | Tremor in selected younger patients; acute dystonia and drug-induced parkinsonism. Avoid routine use in older/cognitively impaired patients. |
Levodopa with Carbidopa or Benserazide
Mechanism and pharmacodynamics
Levodopa crosses the blood–brain barrier and is converted to dopamine by aromatic L-amino-acid decarboxylase. Carbidopa or benserazide acts mainly outside the brain, reducing peripheral conversion. This increases levodopa reaching the brain and reduces peripheral nausea, vomiting, tachycardia and hypotension. The combination particularly improves bradykinesia and rigidity.
Pharmacokinetics
- Absorbed mainly from the proximal small intestine; gastric delay and constipation make response unpredictable.
- Levodopa competes with large neutral amino acids from high-protein meals for intestinal absorption and transport into the brain.
- Plasma half-life is short—approximately 1–2 hours—so repeated dosing is usually required.
- Peripheral decarboxylase inhibitors do not significantly cross the blood–brain barrier.
Indications and representative adult dosing
Used for symptomatic Parkinson disease and parkinsonism where a specialist considers dopaminergic replacement appropriate. A commonly used immediate-release starting regimen is carbidopa/levodopa 25/100 mg orally three times daily, titrated gradually to response and tolerability. Formulations and ratios vary; the prescribed product must be followed exactly. Dose changes are individualised and not made independently by the nurse.
Adverse effects
- Early/peripheral: nausea, vomiting, anorexia, postural hypotension, dizziness and cardiac rhythm disturbance.
- Neuropsychiatric: confusion, vivid dreams, hallucinations, agitation, delusions and impulse-control problems.
- Motor complications: dyskinesia; end-of-dose wearing-off; delayed “on”; unpredictable on–off fluctuations; painful dystonia.
- Harmless changes: saliva, sweat or urine may become dark; explain this while checking that discoloration is not haematuria or another illness.
Contraindications, precautions and interactions
- Use specialist caution in active psychosis, severe cardiovascular disease, glaucoma, melanoma history/suspicious skin lesion and peptic ulcer history.
- Non-selective monoamine oxidase inhibitors can cause dangerous hypertension and require an appropriate washout; verify the medicine list.
- Dopamine-blocking antipsychotics and metoclopramide may reduce benefit and worsen parkinsonism. Antipsychotic selection in Parkinson disease needs specialist input.
- Antihypertensives increase postural hypotension; iron salts may reduce levodopa absorption—separate when prescribed.
- High-protein meals may reduce or delay effect in some patients; never restrict protein dangerously—dietary timing should be individualised with dietetic/clinical advice.
Never stop levodopa suddenly. Abrupt withdrawal or major dose reduction may produce severe rigidity, fever, altered consciousness and autonomic instability resembling neuroleptic malignant syndrome. Treat as an emergency and seek urgent medical review.
Dopamine Agonists
These medicines directly stimulate dopamine receptors and do not require conversion to dopamine. Non-ergot agents are generally preferred to ergot derivatives.
| Medicine | Pharmacokinetics and representative dose | Important adverse effects/monitoring |
|---|---|---|
| Pramipexole | Renally eliminated largely unchanged; immediate-release is often started at 0.125 mg three times daily and titrated slowly. Reduce in renal impairment. | Nausea, oedema, hypotension, hallucinations, sudden sleep, impulse-control disorder and withdrawal syndrome. |
| Ropinirole | Hepatic CYP1A2 metabolism; immediate-release often starts at 0.25 mg three times daily with weekly titration. Smoking changes may alter exposure. | Somnolence, sudden sleep attacks, dizziness, hypotension, hallucinations, dyskinesia and compulsive behaviours. |
| Rotigotine patch | Continuous transdermal delivery; dose varies by stage. Apply once daily to a different site. | Skin reactions plus class effects; document patch removal to prevent accidental duplication. |
| Apomorphine | Rapid subcutaneous rescue/intermittent injection or infusion for advanced disease; initiated and titrated by a specialist. | Profound nausea, hypotension, somnolence, nodules, hallucinations and QT concerns. Concomitant 5-HT3 antagonists such as ondansetron are contraindicated because of severe hypotension/loss of consciousness. |
| Bromocriptine/cabergoline | Longer-acting ergot derivatives; specialist-only selection. | Cardiac valvular, pulmonary/retroperitoneal fibrosis; baseline and ongoing cardiac/fibrotic monitoring is required. |
Impulse-control disorders
Dopamine agonists may cause gambling, hypersexuality, compulsive shopping, binge eating, punding or excessive medication use. Risk may not be volunteered. Educate the patient and family/carer before treatment, ask privately and repeatedly, document impact, and refer promptly for prescriber review. Do not shame the patient or simply stop the medicine abruptly.
Withdrawal
Sudden reduction can produce anxiety, panic, depression, pain, fatigue, sweating and drug craving. Taper only according to the prescriber’s plan.
Monoamine Oxidase-B Inhibitors
| Drug | Action and dose | Adverse effects and interactions |
|---|---|---|
| Selegiline | Irreversibly inhibits MAO-B, reducing dopamine breakdown. Common oral total is 5–10 mg/day; give earlier in the day because amphetamine-like metabolites may cause insomnia. | Nausea, dizziness, hypotension, insomnia, hallucinations and dyskinesia when combined with levodopa. |
| Rasagiline | Irreversible MAO-B inhibitor; commonly 1 mg once daily. | Headache, influenza-like symptoms, hypotension, hallucinations and increased levodopa adverse effects. |
| Safinamide | Reversible MAO-B inhibition plus modulation of glutamate release; adjunct for fluctuations, commonly 50 mg daily then 100 mg if prescribed. | Dyskinesia, insomnia, dizziness and interaction precautions similar to other MAO-B inhibitors. |
- Avoid combining with other MAO inhibitors, sympathomimetics or certain serotonergic medicines unless specialist guidance confirms safety.
- Opioids with serotonergic properties—especially pethidine/meperidine, tramadol or methadone—may cause severe reactions; verify interaction resources.
- Watch for serotonin syndrome: agitation, sweating, diarrhoea, fever, tremor, clonus and hyperreflexia. Stop suspected agents according to emergency protocol and obtain urgent medical care.
COMT Inhibitors
Entacapone, opicapone and tolcapone inhibit catechol-O-methyl transferase and prolong levodopa action. They are adjuncts for wearing-off, not effective standalone dopamine replacement.
| Medicine | Representative administration | Key risks |
|---|---|---|
| Entacapone | Usually 200 mg with each levodopa/dopa-decarboxylase-inhibitor dose, within product maximum. | Increased dyskinesia, diarrhoea, nausea, hypotension and harmless orange-brown urine. |
| Opicapone | Long-acting, commonly 50 mg once nightly, separated from food according to product directions. | Dyskinesia, constipation, dry mouth, hypotension and hallucinations. |
| Tolcapone | Potent central/peripheral action; restricted specialist use. | Potentially fatal hepatotoxicity; requires strict liver monitoring and is avoided where safer alternatives work. |
When a COMT inhibitor is added, levodopa may need reduction because dopaminergic adverse effects intensify. Nurses report new dyskinesia, confusion or hypotension rather than withholding doses without an order.
Amantadine
Pharmacology
Amantadine increases dopamine release, reduces reuptake and antagonises N-methyl-D-aspartate (NMDA) receptors. It may provide modest benefit for motor symptoms and is particularly used to reduce dyskinesia.
- Typical adult dosing: commonly 100 mg once daily initially, increasing to 100 mg twice daily when tolerated; specialist regimens vary.
- Elimination: mainly renal; reduce dose in renal impairment and older adults to prevent accumulation.
- Common effects: ankle oedema, nausea, dizziness, insomnia, dry mouth and mottled lace-like skin discoloration (livedo reticularis).
- Serious effects: confusion, hallucinations, agitation, falls and toxicity with renal impairment.
- Interactions: other anticholinergic or stimulating medicines may increase confusion; medicines that affect QT or renal clearance require review.
- Withdrawal: avoid abrupt cessation after regular use because severe deterioration, delirium or a malignant-like syndrome can occur.
Central Antimuscarinic Medicines
Trihexyphenidyl (benzhexol), benztropine, biperiden and procyclidine reduce cholinergic activity in the basal ganglia. They improve tremor and rigidity more than bradykinesia. Because cognitive and peripheral adverse effects are substantial, they are mainly reserved for selected younger patients and antipsychotic-induced extrapyramidal symptoms.
| Medicine | Representative adult dose | Important points |
|---|---|---|
| Trihexyphenidyl/benzhexol | Often start 1 mg/day and titrate gradually; usual divided total 5–15 mg/day depending on indication and response. | Common in psychiatric practice for drug-induced parkinsonism; not prophylaxis for every antipsychotic patient. |
| Benztropine | Oral commonly 0.5–2 mg once or twice daily; IM/IV may be used for acute dystonia according to protocol. | Rapid relief may occur in acute dystonia; observe recurrence after the dose wears off. |
| Biperiden | Oral commonly 2 mg one to four times daily; parenteral dosing for acute dystonia follows local protocol/product information. | WHO essential-medicine discussions include it among anti-Parkinson medicines; strong anticholinergic precautions apply. |
| Procyclidine | Commonly 2.5 mg three times daily, titrated; usual total 10–30 mg/day. | Used for antipsychotic-induced parkinsonism and acute dystonia in some settings. |
Contraindications and adverse effects
- Peripheral anticholinergic effects: dry mouth, blurred vision, constipation, urinary retention, tachycardia, reduced sweating and heat intolerance.
- Central effects: impaired memory, confusion, agitation, hallucinations, delirium and misuse/euphoria.
- Avoid or use extreme caution in narrow-angle glaucoma, prostatic obstruction/urinary retention, paralytic ileus, severe constipation, tachyarrhythmia, myasthenia gravis and older people with cognitive impairment.
- Additive toxicity occurs with tricyclic antidepressants, sedating antihistamines, antipsychotics with antimuscarinic activity and other anticholinergics.
Tardive dyskinesia warning: anticholinergics do not treat tardive dyskinesia and may worsen it. Differentiate rhythmic oro-facial/choreoathetoid tardive movements from acute dystonia or drug-induced parkinsonism, notify the prescriber and follow a specific tardive-dyskinesia plan.
Antipsychotic-Induced Extrapyramidal Symptoms
| Syndrome and timing | Clinical features | Management principles |
|---|---|---|
| Acute dystonia: hours–days | Painful neck twisting, jaw spasm, tongue protrusion, oculogyric crisis; laryngeal dystonia may threaten airway. | ABCDE; urgent parenteral anticholinergic/antihistamine per protocol; airway help for stridor; continue short oral cover if prescribed; review antipsychotic. |
| Akathisia: days–weeks | Inner restlessness, pacing, inability to sit; may be mistaken for agitation/anxiety and is associated with severe distress. | Review dose/switch; propranolol or other targeted treatment may be prescribed. Anticholinergics are usually less effective unless parkinsonism coexists. |
| Drug-induced parkinsonism: weeks–months | Bradykinesia, rigidity, masked face, shuffling gait, often bilateral tremor. | Reduce/switch causative medicine when safe; short-term antimuscarinic or amantadine may be prescribed. Review regularly and withdraw when no longer needed. |
| Tardive dyskinesia: months–years | Chewing, tongue, facial, trunk or limb movements that may persist. | Do not add routine anticholinergic; specialist antipsychotic review and targeted therapy. |
| Neuroleptic malignant syndrome | Fever, severe rigidity, altered consciousness and autonomic instability; raised creatine kinase may occur. | Medical emergency: stop dopamine blocker under emergency protocol, urgent hospital care, cooling, fluids, monitoring and specialist treatment. |
Safe Medicine Administration
| No. | Nursing action | Rationale |
|---|---|---|
| 1 | Complete medication reconciliation including exact formulation, strength and usual times; ask patient/caregiver and check containers/records. | Parkinson medicines are time-critical; substitution or delay can cause profound immobility and aspiration risk. |
| 2 | Administer at the patient’s individual scheduled time—not merely the ward drug-round time. | Maintains mobility, swallowing and predictable “on” periods. |
| 3 | Assess swallowing before oral administration and involve speech/swallow specialists when unsafe. | Parkinson disease increases dysphagia and aspiration; crushing modified-release products may be dangerous. |
| 4 | Measure lying/sitting and standing blood pressure when indicated; institute fall precautions. | Dopaminergic medicines commonly cause orthostatic hypotension. |
| 5 | Observe “on/off” timing, tremor, rigidity, gait, freezing and dyskinesia relative to each dose. | A precise diary guides rational adjustment better than “medicine not working.” |
| 6 | Ask about hallucinations, sleep attacks, gambling, sexual behaviour, shopping and eating changes sensitively and privately. | Neuropsychiatric effects may be hidden through shame or lack of insight. |
| 7 | Monitor bowel, bladder, mouth, vision, cognition and temperature tolerance with anticholinergics. | Detects urinary retention, ileus, glaucoma symptoms and delirium early. |
| 8 | Do not omit or abruptly stop dopaminergic therapy; urgently contact the prescriber if nil by mouth, vomiting or surgery prevents dosing. | Alternative routes/timing may be required to prevent severe withdrawal deterioration. |
| 9 | Document response, adverse effects, falls, missed/late doses and escalation clearly during handover. | Maintains continuity and prevents repeated medication error. |
Baseline and Ongoing Monitoring
- Motor symptoms and function: walking, transfers, speech, swallowing, self-care, falls and patient-defined goals.
- Blood pressure, pulse, weight and oedema; ECG when cardiac risk/product guidance indicates.
- Cognition, delirium, mood, psychosis, sleepiness and impulse-control behaviours.
- Renal function for pramipexole/amantadine; liver function where product/medicine such as tolcapone requires it.
- Skin and eye review according to clinical risk; review suspicious pigmented lesions.
- For ergot agonists: specialist cardiac valve and fibrotic surveillance.
- Medication timing, adherence, food relationship, duration of “on,” wearing-off and dyskinesia diary.
Patient and Family Education
- Take each dose at the exact agreed time and keep an updated medicine list.
- Do not stop treatment suddenly or double a missed dose unless specifically instructed.
- Rise slowly, hydrate appropriately and request review after fainting or repeated falls.
- Do not drive or operate machinery if suddenly sleepy; report sleep attacks immediately.
- Report hallucinations, marked confusion, new compulsive behaviour, severe vomiting, palpitations or uncontrolled movements.
- Use a timing/symptom diary and bring it to appointments.
- Maintain balanced nutrition; discuss protein redistribution only with the clinical/dietetic team.
- Exercise, physiotherapy, occupational therapy and speech/swallow therapy remain essential; medicines alone do not address all disability.
Special Populations
- Older adults: start low and titrate slowly; hallucinations, hypotension, falls and anticholinergic delirium are more likely.
- Renal impairment: pramipexole and amantadine commonly require dose reduction.
- Hepatic impairment: check medicines with significant hepatic metabolism or hepatotoxicity; tolcapone is especially restricted.
- Pregnancy/breastfeeding: evidence is limited and drug-specific; specialist assessment is required. Dopamine agonists may suppress lactation.
- Psychosis/dementia: balance motor benefit against hallucinations/confusion; changes require Parkinson/mental-health specialist coordination.
Common Examination Traps
- Carbidopa does not treat symptoms alone; it prevents peripheral levodopa breakdown.
- Entacapone has no useful anti-Parkinson effect without levodopa.
- Levodopa is not routine treatment for antipsychotic-induced parkinsonism and may worsen psychosis.
- Anticholinergics may treat acute dystonia or drug-induced parkinsonism but may worsen tardive dyskinesia.
- Akathisia is subjective inner restlessness, not simply aggressive behaviour.
- Parkinson medicines are time-critical; late doses may cause immobility and unsafe swallowing.
- Abrupt withdrawal of levodopa, dopamine agonists or amantadine can be dangerous.
DOPAMINE safety: Doses on time; On/off diary; Postural BP and psychosis; Avoid abrupt stopping; Monitor movements; Impulse-control enquiry; Nutrition/interactions; Educate and escalate.
References
- World Health Organization. Parkinson disease fact sheet.
- WHO. Parkinson disease: a public health approach.
- NICE NG71. Parkinson’s disease in adults: recommendations.
- WHO Essential Medicines review: levodopa with carbidopa for Parkinson disease.
- Consult current product information, specialist guidance and the applicable Uganda Essential Medicines and Health Supplies List for availability, formulations and local prescribing requirements.